MedTrace Logo

the Safety and Efficacy of N-acetyl Cysteine in Children With Drug-Resistant Epilepsy

NCT05485558 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-07-01

No results posted yet for this study

Summary

This study aims at investigating the possible efficacy and safety of N-acetyl cysteine as adjuvant therapy in the treatment of drug-resistant epilepsy

Conditions

  • Drug Resistant Epilepsy

Interventions

DRUG

N-acetyl cysteine

10 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.

DRUG

Placebo

15 patients will receive standard antiepileptic drug plus placebo capsules for 6 months.

DRUG

NAc

40 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Ahmed kishk, Lecturer · Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-15
Primary Completion
2024-06-01
Completion
2025-01-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05485558 on ClinicalTrials.gov